Relief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laboratory

Relief Therapeutics Holding SA / Key word(s): Regulatory Approval Relief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laboratory 15.05.2023 / 07:00 CET/CEST Relief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laboratory

The state-of-the-art quality control and research and development laboratory in Balerna, Switzerland is run by APR Applied Pharma Research SA, a Relief Therapeutics subsidiary

GENEVA (May 15, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFFD, RLFTD) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes to benefit those suffering from select specialty and rare diseases, today announced its new state-of-the-art laboratory has been audited and approved by the Swiss Agency for Therapeutic Products (Swissmedic) and meets Good Manufacturing Practice (GMP) standards. Swissmedic is the national authorization and supervisory authority for drugs and medical products and devices.

The next-generation laboratory in Balerna, Switzerland is run by Relief Therapeutics’ subsidiary APR Applied Pharma Research SA (APR) and offers a comprehensive suite of analytical and development services for internal projects and provides external clients with data and full documentation to meet current Good Manufacturing Practice (cGMP), International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) and international regulatory authority requirements.

“GMP compliance is a critical achievement for our laboratory, enabling us to create, safeguard and supply high-quality products to patients and healthcare providers as well as enable the future submissions of product files to regulatory authorities,” said Paolo Galfetti, chief operating officer of Relief Therapeutics and chief executive officer of APR. “Our new GMP lab is designed to meet forthcoming pharmaceutical challenges and is fully integrated with the current technical and analytical R&D capabilities, with more than 800 m² equipped for analytical and formulation development of solid and non-solid dosage forms.”